Dr. Sarit Assouline CML Chronic Myeloid Leukemia
Assistant Professor
Jewish General Hospital
Department of Oncology
Gerald Bronfman Centre
Montreal, Canada
Leukemia: articles by Sarit E. Assouline - Expertscape
Jewish General Hospital
Department of Oncology
Gerald Bronfman Centre
Montreal, Canada
Leukemia: articles by Sarit E. Assouline - Expertscape
ARTICLES
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
November 5, 2020, Blood
Chronic myelogenous leukemia presenting as central retinal vein occlusion.
June 22, 2020, Taylor and Francis Online
Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation
June 9, 2020, Blood
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
January 10, 2019, Haematologica
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response
October 2017, PubMed
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
September 15, 2016, PubMed
Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia
2016, Journal of Oncology Practice
Major discovery on the mechanism of drug resistance in leukemia and other cancers
May 28, 2014, Science Daily
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated with Imatinib
2011, Journal of the National Cancer Institute (JNCI) - Medscape
Monitoring response and resistance to treatment in chronic myeloid leukemia
April 2011, Current Oncology
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
February 2008, Haematologica
Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia
2006, Journal Blood
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
November 5, 2020, Blood
Chronic myelogenous leukemia presenting as central retinal vein occlusion.
June 22, 2020, Taylor and Francis Online
Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation
June 9, 2020, Blood
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
January 10, 2019, Haematologica
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response
October 2017, PubMed
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
September 15, 2016, PubMed
Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia
2016, Journal of Oncology Practice
Major discovery on the mechanism of drug resistance in leukemia and other cancers
May 28, 2014, Science Daily
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated with Imatinib
2011, Journal of the National Cancer Institute (JNCI) - Medscape
Monitoring response and resistance to treatment in chronic myeloid leukemia
April 2011, Current Oncology
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
February 2008, Haematologica
Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia
2006, Journal Blood
